share_log

開拓藥業-B：截至2023年12月31日止年度之年度業績公告

KINTOR PHARMA-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 28 08:11
Summary by Moomoo AI
開拓藥業-B（開拓藥業有限公司）於2023年12月31日公佈年度業績，研發成本較去年同期減少489.2百萬元人民幣，降幅達66.6%，主要因核心產品KX-826和GT20029研發投入減少。行政開支亦減少45.8百萬元人民幣，降幅34.6%，由於員工薪酬及股權激勵費用減少。公司未來將聚焦皮科領域，加強核心產品商業化。年內虧損及全面虧損總額為人民幣1,060.8百萬元，較去年增加106.4百萬元。董事會決議不派發任何末期股息。公司股份於香港聯合交易所有限公司主板上市。
開拓藥業-B（開拓藥業有限公司）於2023年12月31日公佈年度業績，研發成本較去年同期減少489.2百萬元人民幣，降幅達66.6%，主要因核心產品KX-826和GT20029研發投入減少。行政開支亦減少45.8百萬元人民幣，降幅34.6%，由於員工薪酬及股權激勵費用減少。公司未來將聚焦皮科領域，加強核心產品商業化。年內虧損及全面虧損總額為人民幣1,060.8百萬元，較去年增加106.4百萬元。董事會決議不派發任何末期股息。公司股份於香港聯合交易所有限公司主板上市。
KYOTO PHARMACEUTICAL-B (KAITO PHARMACEUTICALS CO., LTD.) ANNOUNCED ITS ANNUAL RESULTS ON DECEMBER 31, 2023. R&D COSTS DECREASED BY RMB 489.2 MILLION COMPARED TO THE SAME PERIOD LAST YEAR, DOWN BY 66.6%, MAINLY DUE TO A DECREASE IN R&D INVESTMENT FOR ITS CORE PRODUCTS KX-826 AND GT20029. Administrative expenses also decreased by RMB45.8 million, down 34.6% due to lower employee remuneration and equity incentive expenses. In the future, the company will focus on the Picco area and strengthen the commercialization of its core products. The year-over-year loss and comprehensive loss totaled RMB1,060.8 million, an increase of $106.4 million over the previous year. THE BOARD OF DIRECTORS RESOLVES NOT TO DISTRIBUTE ANY FINAL DIVIDENDS. The company's shares are listed on the Main Board of the Hong Kong Stock Exchange Limited.
KYOTO PHARMACEUTICAL-B (KAITO PHARMACEUTICALS CO., LTD.) ANNOUNCED ITS ANNUAL RESULTS ON DECEMBER 31, 2023. R&D COSTS DECREASED BY RMB 489.2 MILLION COMPARED TO THE SAME PERIOD LAST YEAR, DOWN BY 66.6%, MAINLY DUE TO A DECREASE IN R&D INVESTMENT FOR ITS CORE PRODUCTS KX-826 AND GT20029. Administrative expenses also decreased by RMB45.8 million, down 34.6% due to lower employee remuneration and equity incentive expenses. In the future, the company will focus on the Picco area and strengthen the commercialization of its core products. The year-over-year loss and comprehensive loss totaled RMB1,060.8 million, an increase of $106.4 million over the previous year. THE BOARD OF DIRECTORS RESOLVES NOT TO DISTRIBUTE ANY FINAL DIVIDENDS. The company's shares are listed on the Main Board of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more